Editorial
doi: 10.1210/clinem/dgad513.
Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!
Affiliations
- PMID: 37650613
- DOI: 10.1210/clinem/dgad513
Item in Clipboard
Editorial
Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!
J Clin Endocrinol Metab.
.
No abstract available
Keywords: 21-hydroxylase; ACTH; CAH; CRH; CRH receptor; antalarmin; glucocorticoids; stresscopin; tildacerfont; urocortin.
Comment on
-
Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia.J Clin Endocrinol Metab. 2023 Oct 18;108(11):2871-2878. doi: 10.1210/clinem/dgad270. J Clin Endocrinol Metab. 2023. PMID: 37216921 Free PMC article.
Similar articles
-
CRH receptor antagonist crinecerfont - a promising new treatment option for patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.J Pediatr Endocrinol Metab. 2024 Nov 25;38(1):16-21. doi: 10.1515/jpem-2024-0440. Print 2025 Jan 29. J Pediatr Endocrinol Metab. 2024. PMID: 39576723
-
Crinecerfont: First Approval.Drugs. 2025 Jun;85(6):839-843. doi: 10.1007/s40265-025-02165-1. Epub 2025 Apr 17. Drugs. 2025. PMID: 40240539 Review.
-
Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia.J Clin Endocrinol Metab. 2023 Oct 18;108(11):2871-2878. doi: 10.1210/clinem/dgad270. J Clin Endocrinol Metab. 2023. PMID: 37216921 Free PMC article.
-
Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia.J Clin Endocrinol Metab. 2022 Feb 17;107(3):801-812. doi: 10.1210/clinem/dgab749. J Clin Endocrinol Metab. 2022. PMID: 34653252 Free PMC article. Clinical Trial.
-
Milestones in CRH Research.Curr Mol Pharmacol. 2017;10(4):259-263. doi: 10.2174/1874467210666170109165219. Curr Mol Pharmacol. 2017. PMID: 28071586 Review.
Cited by
-
Design, Synthesis, and Biological Evaluations of Novel Thiazolo[4,5-d]pyrimidine Corticotropin Releasing Factor (CRF) Receptor Antagonists as Potential Treatments for Stress Related Disorders and Congenital Adrenal Hyperplasia (CAH).Molecules. 2024 Aug 1;29(15):3647. doi: 10.3390/molecules29153647. Molecules. 2024. PMID: 39125051 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
